60 Degrees Pharma Submits Statistical Plan for Tafenoquine Trial, Eyes Priority Review Voucher
SXTP sits 30% above its 52-week low of $1.22 on light trading volume (0.3× avg).
Summary
60 Degrees Pharmaceuticals filed a statistical analysis plan with the FDA for its tafenoquine babesiosis trial, setting the stage for a potential interim analysis by October 2026. The company also announced plans to seek a Priority Review Voucher if the data supports an sNDA submission.
Key Events · Product Development and Regulatory · SXTP
-
Statistical Analysis Plan Submitted to FDA
On July 7, 2026, the SAP for the tafenoquine babesiosis trial was submitted, outlining the interim analysis methodology and stopping rules.
-
Interim Analysis Trigger Set
The interim analysis will occur at the earlier of October 30, 2026 or after 24 of 33 planned patients are randomized with 50-day follow-up. Conditional power ≥80% may allow early reporting of positive results.
-
Priority Review Voucher Application Planned
If trial results support an sNDA submission, the company intends to apply for a Commissioner's National Priority Review Voucher, a potentially valuable asset.
-
Enrollment Progress: 23 of 33 Patients
As of the filing date, 23 patients have been enrolled, nearing the 24-patient threshold that could trigger the interim analysis.
Analysis · SXTP · Life Sciences
A statistical analysis plan has been submitted to the FDA for the interim analysis of the tafenoquine trial in severe babesiosis, setting clear triggers: an interim look by October 30, 2026 or after 24 patients are randomized with 50-day follow-up. If conditional power reaches at least 80%, the trial could stop early for success — a potential catalyst. The company also disclosed its intent to pursue a Priority Review Voucher, which could be worth tens of millions if granted. With 23 patients already enrolled and a cash runway of only four months, this trial represents a critical value driver. Positive interim data could unlock financing or partnership opportunities, while failure would be a major setback.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2797 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTP was trading at $1.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.22 to $10.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.